Effectiveness of Tocilizumab after switching from intravenous to subcutaneous formulation in patients with rheumatoid arthritis: A single-centre experience

By

Sonja Stojanović ,

Sonja Stojanović

View authors publications

Search this author on:

PubMed | Google Scholar

Bojana Stamenković ,

Bojana Stamenković

View authors publications

Search this author on:

PubMed | Google Scholar

Jovan Nedović ,

Jovan Nedović

View authors publications

Search this author on:

PubMed | Google Scholar

Ivana Aleksić ,

Ivana Aleksić

View authors publications

Search this author on:

PubMed | Google Scholar

Jovana Cvetković

Jovana Cvetković

View authors publications

Search this author on:

PubMed | Google Scholar

Abstract

Nowadays, the appropriate control of rheumatoid arthritis (RA) involves the absence of clinical disease activity, delaying joint destruction as long as possible and adequate quality of life of the affected. With currently available therapeutic modalities, this therapeutic goal can be achieved in a large number of patients. The aim of this research was to determine the effectiveness of an IL-6 blocker (Tocilizumab) in patients with RA in everyday clinical practice. We also analyzed whether a change in the mode of drug administration (switching from intravenous to subcutaneous drug formulation) had an impact on drug effectiveness (using the DAS 28 SE and CDAI indexes) and quality of life of patients with RA (HAQ, Beck Depression Inventory, FACIT F score and SF 36 questionnaire). The study included 53 subjects diagnosed with RA, treated with Tocilizumab. After a six-month use of subcutaneous Tocilizumab, we concluded that the method of drug administration did not have an impact on its effectiveness and on all the examined parameters of quality of life assessment.

References

Citation

Copyright

Article metrics